Skip to main content
. 2013 Oct;98(10):1510–1516. doi: 10.3324/haematol.2012.080234

Figure 3.

Figure 3.

Failure-free survival of CP CML patients resistant to IM harboring a T315I mutation, in months, according to the time of detection of the mutation before (dotted line) of after (dashed line) exposure to the TKI2. N: number of patients.